Fate Therapeutics (FATE) Research & Development (2012 - 2026)

Fate Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $24.7 million for Q1 2026.

• Quarterly Research & Development fell 15.21% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.4 million (down 21.67% YoY) and the FY2025 annual result came in at $107.8 million, down 20.13% from the prior year.
• Research & Development was $24.7 million for Q1 2026 at Fate Therapeutics, down from $25.4 million in the prior quarter.
• Across five years, Research & Development topped out at $87.2 million in Q4 2022 and bottomed at $24.7 million in Q1 2026.
• A 5-year average of $44.7 million and a median of $34.3 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development jumped 69.31% — and 2023, when it sank 63.51%.
• Fate Therapeutics' Research & Development stood at $87.2 million in 2022, then tumbled by 63.51% to $31.8 million in 2023, then grew by 5.64% to $33.6 million in 2024, then fell by 24.35% to $25.4 million in 2025, then declined by 2.84% to $24.7 million in 2026.
• Business Quant data shows FATE's Research & Development at $24.7 million in Q1 2026, $25.4 million in Q4 2025, and $25.8 million in Q3 2025.